1. Home
  2. PODD vs PCVX Comparison

PODD vs PCVX Comparison

Compare PODD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insulet Corporation

PODD

Insulet Corporation

HOLD

Current Price

$158.62

Market Cap

10.5B

Sector

Health Care

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$53.72

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PODD
PCVX
Founded
2000
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5B
8.6B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
PODD
PCVX
Price
$158.62
$53.72
Analyst Decision
Buy
Strong Buy
Analyst Count
21
4
Target Price
$341.48
$88.25
AVG Volume (30 Days)
1.4M
1.3M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.30
N/A
Revenue
$2,708,100,000.00
N/A
Revenue This Year
$24.55
N/A
Revenue Next Year
$19.18
N/A
P/E Ratio
$118.53
N/A
Revenue Growth
30.73
N/A
52 Week Low
$148.31
$28.64
52 Week High
$354.88
$65.00

Technical Indicators

Market Signals
Indicator
PODD
PCVX
Relative Strength Index (RSI) 33.41 39.51
Support Level N/A $52.04
Resistance Level $205.95 $56.04
Average True Range (ATR) 8.61 2.70
MACD -1.04 -0.74
Stochastic Oscillator 24.16 39.45

Price Performance

Historical Comparison
PODD
PCVX

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: